Osteoporosis Treatment and Prevention for Postmenopausal Women: Current and Future Therapeutic Options.
|Title||Osteoporosis Treatment and Prevention for Postmenopausal Women: Current and Future Therapeutic Options.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Pinkerton, JV, Thomas S, Dalkin AC|
|Journal||Clinical obstetrics and gynecology|
|Date Published||2013 Oct 4|
Osteoporosis, a "silent disease," is often unrecognized until fracture. Lifestyle modification with nutritional counseling is recommended during menopausal transition. Bone density testing is recommended for women aged 65 years and older, younger postmenopausal women with risk factors, or to follow therapy. Bisphosphonates treat osteoporosis (prevent bone resorption). Raloxifene and hormone therapy prevent bone loss and fracture, with extraskeletal benefits. Denosumab treats osteoporosis, although bone effects reverse rapidly. Teriparatide (anabolic therapy) is considered for women at high risk of fracture. Bazedoxifene with conjugated estrogens, novel delivery of teriparatide, new parathyroid hormone proteins, anti-sclerostin antibodies, cathepsin K inhibitors, and stem cell therapies are in testing.
|Short Title||Clin Obstet Gynecol|